Related Experiment Video
Updated: Feb 3, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Alterations of tumor microenvironment by nitric oxide impedes castration-resistant prostate cancer growth
Himanshu Arora1,2, Kush Panara3, Manish Kuchakulla3
1Department of Urology, Miller School of Medicine, University of Miami, Miami, FL 33136; hxa287@miami.edu andrew.schally@va.gov ramasamy@miami.edu.
Abstract:
Immune targeted therapy of nitric oxide (NO) synthases are being considered as a potential frontline therapeutic to treat patients diagnosed with locally advanced and metastatic prostate cancer. However, the role of NO in castration-resistant prostate cancer (CRPC) is controversial because NO can increase in nitrosative stress while simultaneously possessing antiinflammatory properties. Accordingly, we tested the hypothesis that increased NO will lead to tumor suppression of CRPC through tumor microenvironment. S-nitrosoglutathione (GSNO), an NO donor, decreased the tumor burden in murine model of CRPC by targeting tumors in a cell nonautonomous manner. GSNO inhibited both the abundance of antiinflammatory (M2) macrophages and expression of pERK, indicating that tumor-associated macrophages activity is influenced by NO. Additionally, GSNO decreased IL-34, indicating suppression of tumor-associated macrophage differentiation. Cytokine profiling of CRPC tumor grafts exposed to GSNO revealed a significant decrease in expression of G-CSF and M-CSF compared with grafts not exposed to GSNO. We verified the durability of NO on CRPC tumor suppression by using secondary xenograft murine models. This study validates the significance of NO on inhibition of CRPC tumors through tumor microenvironment (TME). These findings may facilitate the development of previously unidentified NO-based therapy for CRPC.
Insights
Nitric oxide (NO) therapy shows promise for advanced prostate cancer. S-nitrosoglutathione (GSNO) reduced castration-resistant prostate cancer (CRPC) tumor growth by modulating the tumor microenvironment and immune cells.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Nitric oxide (NO) synthases are explored for advanced prostate cancer therapy.
- The role of NO in castration-resistant prostate cancer (CRPC) is debated due to conflicting anti-inflammatory and pro-oxidative effects.
- Understanding NO's impact on the CRPC tumor microenvironment (TME) is crucial.
Purpose of the Study:
- To investigate the hypothesis that increased NO can suppress CRPC growth via TME modulation.
- To evaluate the therapeutic potential of NO donors in CRPC models.
Main Methods:
- Utilized a murine model of CRPC.
- Administered S-nitrosoglutathione (GSNO), an NO donor, to assess tumor burden.
- Analyzed changes in tumor-associated macrophages (M2), pERK expression, IL-34, G-CSF, and M-CSF.
- Validated findings in secondary xenograft models.
Main Results:
- GSNO significantly decreased CRPC tumor burden in mice.
- GSNO inhibited M2 macrophages and pERK expression, suggesting NO influences tumor-associated macrophage activity.
- GSNO suppressed IL-34, indicating reduced tumor-associated macrophage differentiation.
- Reduced G-CSF and M-CSF levels were observed in GSNO-treated CRPC tumors.
- NO's inhibitory effect on CRPC was durable and reproducible.
Conclusions:
- NO plays a significant role in inhibiting CRPC progression through TME regulation.
- GSNO demonstrates therapeutic potential for CRPC by targeting the tumor microenvironment.
- These findings support the development of novel NO-based therapies for CRPC.
Related Concept Videos
The Tumor Microenvironment
Nitric Oxide Signaling Pathway
Treatment Resistant Cancers
Oxidation Numbers
Alterations in Respiration II
In Biot's breathing, the respiratory rate and depth are irregular, alternating between periods of deep gasping and apnea. Common causes...
Impedance Combination

